The US Food and Drug Administration (FDA) has announced new requirements for labeling all opioid pain medications to better inform patients about risks, particularly when taken at high doses or over long periods. Labels must also include information about opioid discontinuation and overdose reversal, treatment guidelines limiting the use of extended-release medications, and warnings about drug interactions and adverse effects including digestive issues and toxic leukoencephalopathy.